These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 26845343

  • 1. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS, Khindri S, Calder N, Machineni S, Hara H, Majumdar T, Febbraro S, Fuhr R, Woessner R.
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [Abstract] [Full Text] [Related]

  • 2. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
    Vaidya SS, Khindri S, Maahs S, Machineni S, Hara H, Juan A, Kaiser G.
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):285-95. PubMed ID: 27310329
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
    Shimada S, Vaidya S, Khindri S, Tashiro N, Cheng Y, Hara H, Majumdar T, Woessner R, Furihata K, Kobayashi K.
    Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
    Vaidya S, Jauernig J, Ethell B, Abdallah N, Machineni S, Drollmann A, Heudi O, Last S, Hahn M, Radhakrishnan R, Ignatenko S, Tillmann HC.
    Pulm Pharmacol Ther; 2020 Oct; 64():101964. PubMed ID: 33035700
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S, Vaidya S, Tillmann HC, Sakita Y, Machineni S, Heudi O, Furihata K.
    BMC Pulm Med; 2021 Jan 07; 21(1):18. PubMed ID: 33413291
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
    Vaidya S, Ziegler D, Tanase AM, Malmqvist U, Kanniess F, Hederer B, Hosoe M.
    Pulm Pharmacol Ther; 2021 Oct 07; 70():102019. PubMed ID: 33771722
    [Abstract] [Full Text] [Related]

  • 7. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
    Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 07; 13():3923-3936. PubMed ID: 30584293
    [Abstract] [Full Text] [Related]

  • 8. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
    Beasley RW, Donohue JF, Mehta R, Nelson HS, Clay M, Moton A, Kim HJ, Hederer BM.
    BMJ Open; 2015 Feb 03; 5(2):e006131. PubMed ID: 25649209
    [Abstract] [Full Text] [Related]

  • 9. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Miller D, Vaidya S, Jauernig J, Ethell B, Wagner K, Radhakrishnan R, Tillmann HC.
    Respir Res; 2020 Sep 23; 21(1):248. PubMed ID: 32967685
    [Abstract] [Full Text] [Related]

  • 10. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct 23; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 11. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
    Buhl R, Nikolaev I, Tillmann HC, Vaidya S, Bartels C, Jain M, Jauernig J, Kerstjens HAM.
    Pulm Pharmacol Ther; 2021 Oct 23; 70():102068. PubMed ID: 34329722
    [Abstract] [Full Text] [Related]

  • 12. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma.
    Bartels C, Jain M, Yu J, Tillmann HC, Vaidya S.
    Eur J Drug Metab Pharmacokinet; 2021 Jul 23; 46(4):487-504. PubMed ID: 34024035
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
    Scosyrev E, van Zyl-Smit R, Kerstjens H, Gessner C, Kornmann O, Jain D, Aubrun E, D'Andrea P, Hosoe M, Pethe A, Brittain D.
    Respir Med; 2021 Jul 23; 180():106311. PubMed ID: 33711782
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S, Sechaud R, Su Z, Tillmann HC, Hara H, Tan X, Hou J, Woessner R, Zhao R.
    Int J Clin Pharmacol Ther; 2017 Feb 23; 55(2):147-155. PubMed ID: 27841152
    [Abstract] [Full Text] [Related]

  • 15. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
    van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, Noga O, Richard A, de Los Reyes A, Shu X, Pethe A, Tanase AM, D'Andrea P, PALLADIUM trial investigators.
    Lancet Respir Med; 2020 Oct 23; 8(10):987-999. PubMed ID: 32653075
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
    Buhl R, Tanase AM, Hosoe M, Cao W, Demin I, Bartels C, Jauernig J, Ziegler D, Patalano F, Hederer B, Kanniess F, Tillmann HC.
    Pulm Pharmacol Ther; 2020 Jun 23; 62():101919. PubMed ID: 32387408
    [Abstract] [Full Text] [Related]

  • 17. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
    Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, Pfister P.
    Respir Med; 2020 Jun 23; 170():106021. PubMed ID: 32843164
    [Abstract] [Full Text] [Related]

  • 18. Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers.
    Jiang J, Li L, Yin H, Woessner R, Emotte C, Li R, Khindri S, Pei H.
    Eur J Drug Metab Pharmacokinet; 2015 Jun 23; 40(2):203-8. PubMed ID: 24705947
    [Abstract] [Full Text] [Related]

  • 19. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
    Brittain D, D'Andrea P, Gruen E, Hosoe M, Jain D, Jauernig J, Pethe A, Scosyrev E, Tanase AM, Tillmann HC.
    Adv Ther; 2022 Jun 23; 39(6):2365-2378. PubMed ID: 35072888
    [Abstract] [Full Text] [Related]

  • 20. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
    Watz H, Hohlfeld JM, Singh D, Beier J, Diamant Z, Liu J, Hua S, Abd-Elaziz K, Pinot P, Jones I, Tillmann HC.
    Respir Res; 2020 Apr 15; 21(1):87. PubMed ID: 32295593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.